###begin article-title 0
###xml 167 171 <span type="species:ncbi:10090">mice</span>
Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice
###end article-title 0
###begin p 1
The first two authors contributed equally to the study.
###end p 1
###begin p 2
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
###end p 2
###begin title 3
Aims
###end title 3
###begin p 4
###xml 0 6 <span type="species:ncbi:9606">Humans</span>
###xml 646 652 <span type="species:ncbi:10090">murine</span>
###xml 670 675 <span type="species:ncbi:9606">human</span>
Humans with inactivating mutations in peroxisomal proliferators activated receptor gamma (PPARgamma) typically develop a complex metabolic syndrome characterized by insulin resistance, diabetes, lipodystrophy, hypertension, and dyslipidaemia which is likely to increase their cardiovascular risk. Despite evidence that the activation of PPARgamma may prevent cardiac fibrosis and hypertrophy, recent evidence has suggested that pharmacological activation of PPARgamma causes increased cardiovascular mortality. In this study, we investigated the effects of defective PPARgamma function on the development of cardiac fibrosis and hypertrophy in a murine model carrying a human dominant-negative mutation in PPARgamma.
###end p 4
###begin title 5
Methods and results
###end title 5
###begin p 6
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
Mice with a dominant-negative point mutation in PPARgamma (P465L) and their wild-type (WT) littermates were treated with either subcutaneous angiotensin II (AngII) infusion or saline for 2 weeks. Heterozygous P465L and WT mice developed a similar increase in systolic blood pressure, but the mutant mice developed significantly more severe cardiac fibrosis to AngII that correlated with increased expression of profibrotic genes. Both groups similarly increased the heart weight to body weight ratio compared with saline-treated controls. There were no differences in fibrosis between saline-treated WT and P465L mice.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 142 150 <span type="species:ncbi:9606">patients</span>
These results show synergistic pathogenic effects between the presence of defective PPARgamma and AngII-induced hypertension and suggest that patients with PPARgamma mutation and hypertension may need more aggressive therapeutic measures to reduce the risk of accelerated cardiac fibrosis.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 510 511 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C1">1</xref>
###xml 510 511 502 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C1">1</xref></sup>
###xml 639 640 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C2">2</xref>
###xml 639 640 627 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C2">2</xref></sup>
###xml 783 784 767 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C3">3</xref>
###xml 783 784 767 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C3">3</xref></sup>
###xml 1042 1043 1022 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C4">4</xref>
###xml 1044 1045 1024 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C5">5</xref>
###xml 1042 1045 1022 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C4">4</xref>,<xref ref-type="bibr" rid="HFP048C5">5</xref></sup>
###xml 258 264 <span type="species:ncbi:9606">humans</span>
###xml 1278 1286 <span type="species:ncbi:9606">patients</span>
###xml 1403 1408 <span type="species:ncbi:10090">mouse</span>
###xml 1447 1452 <span type="species:ncbi:9606">human</span>
Peroxisomal proliferators activated receptor gamma (PPARgamma) is an important transcription factor that controls metabolic aspects such as adipogenesis and insulin sensitivity. Its relevance in controlling energy homeostasis is illustrated by the fact that humans with mutations in PPARgamma typically develop severe metabolic complications characterized by insulin resistance, diabetes, lipodystrophy, hypertension, and dyslipidaemia; a cluster of metabolic alterations known to increase cardiovascular risk.1 There is evidence that the activation of PPARgamma using thiazolidinediones improves the metabolic control of diabetic patients2 and that agonism of the PPARgamma receptor may provide added beneficial cardiovascular effects by preventing cardiac fibrosis and hypertrophy.3 However, the potential cardiovascular beneficial effects of PPARgamma agonism have recently been questioned based on the evidence that rosiglitazone treatment to diabetic individuals may cause an increase in cardiovascular mortality of an unclear mechanism.4,5 This observation has important clinical implications not only for its impact of treatment with PPARgamma agonists on the therapeutic management and mental health of the diabetic population, but also for a relatively small subset of patients with mutations in PPARgamma affected by a severe metabolic phenotype. In this study, we use a genetically humanized mouse model harbouring a well-characterized human PPARgamma dominant-negative mutation to determine the effects of defective PPARgamma function on cardiac contraction, fibrotic and hypertrophic responses under basal conditions and in the context of angiotensin II (AngII)-induced hypertension.
###end p 10
###begin p 11
###xml 346 347 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C6">6</xref>
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C6">6</xref></sup>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C7">7</xref>
###xml 384 385 384 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C7">7</xref></sup>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C7">7</xref>
###xml 587 588 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C7">7</xref></sup>
###xml 716 717 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C8">8</xref>
###xml 716 717 716 717 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C8">8</xref></sup>
Hypertensive heart disease and cardiac hypertrophy, often associated with insulin resistance, are leading causes of high morbidity and mortality due to the predisposition to the development of congestive cardiac failure and sudden death. During this process, remodelling of the heart takes place contributing to persistent contractile dysfunction6 and in numerous cases to arrhythmia.7 Although the precise mechanisms underlying cardiac remodelling remain under intensive investigation, the involvement of increased activity of the renin-angiotensin-aldosterone system is well recognised7-as indicated by experimental models of aldosterone or AngII-induced hypertension where a similar process of remodelling occurs.8
###end p 11
###begin p 12
###xml 345 346 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 425 426 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C9">9</xref>
###xml 427 429 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C10">10</xref>
###xml 425 429 409 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C9">9</xref>,<xref ref-type="bibr" rid="HFP048C10">10</xref></sup>
###xml 635 637 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C10">10</xref>
###xml 635 637 615 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C10">10</xref></sup>
###xml 406 409 <span type="species:ncbi:10116">rat</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
Despite its low abundance in the heart, a direct role of PPARgamma in cardiac hypertrophy has been hypothesised previously. It has been suggested that maximal transcriptional activity of PPARgamma may delay the development of this pathological condition as indicated by the fact that ligands of PPARgamma (troglitazone, pioglitazone, 15delta-PGJ2) are able to prevent AngII-induced hypertrophy of neonatal rat cardiomyocytes.9,10 Conversely, pioglitazone only marginally attenuated the hypertrophic response during pressure overload in mice that were heterozygous for deficient PPARgamma compared with their wild-type (WT) littermates.10
###end p 12
###begin p 13
###xml 290 292 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C11">11</xref>
###xml 290 292 286 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C11">11</xref></sup>
###xml 318 320 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C12">12</xref>
###xml 318 320 314 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C12">12</xref></sup>
###xml 636 638 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C13">13</xref>
###xml 636 638 624 626 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C13">13</xref></sup>
###xml 546 550 <span type="species:ncbi:10116">rats</span>
The role of PPARgamma in cardiac fibrosis is not fully understood. Remodelling and fibrosis take place following myocardial ischaemia, with an increase in myocardial collagen deposition, and predisposes to the development of heart failure. There is data suggesting that pioglitazone in mice11 and rosiglitazone in rats12 may reduce post-ischaemic myocardial collagen content and the degree of fibrosis, when these PPARgamma ligands were administered after ischaemia. Similarly, in cardiac hypertrophy induced by transverse aortic constriction in rats, the PPARgamma ligand rosiglitazone reduced collagen deposition and cardiac fibrosis.13
###end p 13
###begin p 14
###xml 73 78 <span type="species:ncbi:9606">human</span>
In this study, we use a genetic approach to investigate the effects of a human equivalent mutation of PPARgamma (P465L dominant-negative point mutation) on the hypertrophic and fibrotic responses to chronic AngII-induced hypertension.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Animals
###end title 16
###begin p 17
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C14">14</xref>
###xml 99 101 99 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C14">14</xref></sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
Peroxisomal proliferators activated receptor gamma (P465L) mice were generated as described before.14 The age of 14-week-old male WT and heterozygous (P465L) littermate mice carrying 'knock-in' mutation were used in this study. Homozygous allelic combination of this mutation causes embryonic lethality. Experiments were performed in accordance with the Guidance on the Operation of Animals (Scientific Procedure) Acts, 1986 (UK).
###end p 17
###begin title 18
Experimental protocol
###end title 18
###begin p 19
###xml 117 119 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 123 125 123 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 227 228 227 228 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 442 443 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 571 572 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 331 335 <span type="species:ncbi:10090">mice</span>
###xml 399 403 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 527 531 <span type="species:ncbi:10090">mice</span>
Osmotic minipumps (Alzet Model 1002, Charles River UK Ltd, Margate, UK) releasing either AngII at a dose of 1.1 mg kg-1 day-1 for 14 days or saline were implanted subcutaneously under isoflurane anaesthesia (2% isoflurane+98% O2). Wild-type and P465L heterozygous animals were randomized into the following experimental groups: WT mice treated with saline (WT/Sal; total n = 11), P465L heterozygous mice treated with saline (P465L/Sal; total n = 11), WT mice treated with AngII (WT/AngII; total n = 21), and P465L heterozygous mice treated with AngII (P465L/AngII; total n = 22).
###end p 19
###begin title 20
Non-invasive blood pressure measurement
###end title 20
###begin p 21
###xml 113 117 <span type="species:ncbi:10090">mice</span>
Systolic blood pressure was measured by tail cuff plethysmography (Kent Scientific, Kings Hill, UK) in conscious mice at a temperature of 26degreesC following a 3 days training session. Blood pressure was measured on day 0, 7, and 14.
###end p 21
###begin title 22
Cardiac functional assessment by echocardiography
###end title 22
###begin p 23
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 120 121 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 298 300 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C15">15</xref>
###xml 298 300 296 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C15">15</xref></sup>
Under isoflurane anaesthesia (1.5% isoflurane and 98.5% O2), animals were placed on a heating pad in a supine position (n >/= 6 per group). Echocardiographic images were acquired using a Sonos 5500 ultrasound system with a 15 MHz linear probe (Philips, Bothell, Washington) as described previously.15 Two-dimensional LV short-axis views were acquired at the papillary muscle level and M-mode recordings were made. Depth settings were adjusted to maximize frame rate (220-260 Hz) and optimize temporal resolution. The interventricular septal thickness in diastole and the left ventricular end-diastolic and end-systolic dimensions were measured using three consecutive cycles. Fractional shortening and heart rate were calculated. Echocardiography was performed at day 7 and 14.
###end p 23
###begin title 24
Tissue collection and histology
###end title 24
###begin p 25
###xml 509 510 505 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
At the end of the 14 days treatment, animals were sacrificed and body weight, atrial, right ventricular and left ventricular weights were measured. Upon tissue harvest, one third of the left ventricle (base) was separated for histological analysis approximately at the level of the papillary muscles and the remaining tissue was frozen in liquid nitrogen. Interstitial fibrosis was determined on formalin fixed, paraffin-embedded 4 microm thick whole left ventricular sections using picrosirius red staining (n = 6-10 per group). The density of collagen (pixel number) in heart sections was measured under polarized light based on its birefringement property at x200 magnification in areas selected randomly, and was expressed as a percentage in relation to the total pixel number.
###end p 25
###begin title 26
Real-time polymerase chain reaction
###end title 26
###begin p 27
###xml 511 512 511 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 994 995 990 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="HFP048TB1">1</xref>
###xml 988 995 984 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="HFP048TB1">1</xref></italic>
Approximately 70-80 mg of frozen left ventricular tissue was used for total RNA extraction using Stat-60 (Tel-Test Co, Friendswood, USA). Single strand cDNA was synthesized by Im-Prom II reverse transcriptase according to the manufacturer's instructions (Promega, Southampton, UK) from 1000 ng RNA. Cardiac hypertrophy markers such as atrial natriuretic peptide (ANP), skeletal muscle actin (SKMactin) and cardiac fibrosis markers such as procollagen I and III, thrombospondin 1, and osteopontin were measured (n = 5-6 per group). All genes were normalized to 18S level in individual samples that were measured in duplicates. In addition, PPARgamma1, adiponectin, and reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits (Nox2, Nox4, p22phox, p67phox) mRNA level were also quantified. Real-time polymerase chain reaction (PCR) was performed with SYBR Green technology using Prism 7900 HT system (Applied Biosystems, Warrington, UK). Primer sequences are listed in Table 1.
###end p 27
###begin p 28
Primer sequences used for reverse transcriptase-polymerase chain reaction
###end p 28
###begin title 29
Allele-specific reverse transcriptase-polymerase chain reaction
###end title 29
###begin p 30
###xml 44 46 44 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-</bold>
###xml 108 110 108 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t-</bold>
###xml 733 734 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 734 735 710 711 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 779 780 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 780 781 756 757 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 974 975 950 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 975 976 951 952 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</sub>
###xml 1174 1176 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C16">16</xref>
###xml 1174 1176 1150 1152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C16">16</xref></sup>
###xml 1297 1298 1273 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Forward primers: WT: 5'-gacagacatgagccttcaccc-3' detects the WT allele, whereas P465L: 5'-cagacatgagccttcacct-3' detects the mutated allele. Common reverse primer: 5'-gggtgggactttcctgctaa-3'. Polymerase chain reaction was performed using the Power SYBR Green PCR Mastermix (Applied Biosystems) with and 100 nM primers. Cycling: 2 min at 50degreesC, 10 min at 95degreesC, then 40 cycles of 15 s at 95degreesC and 1 min at 66degreesC. These conditions were set up in order to minimize the cross amplification of alleles. To discard contaminants and RNA, control was used we use as template for the quantitative real-time PCR under the same conditions used in the validation experiments. For mathematical analysis, the crossing points (Ct) values were used for each transcript. The Ct is defined as the point at which fluorescence of the transcript rises significantly above the background fluorescence. The 'fit point method' was performed in the ABI7900HT platform, at which Ct was measured at a constant fluorescence level. Differences in expression between groups were assessed by Pair Wise Fixed Reallocation Randomization Test using the Relative Expression Software Tool.16 Data were corrected using the geometrical average of four different housekeeping genes. Level of probability was set at P < 0.05.
###end p 30
###begin title 31
Serum biochemical parameters
###end title 31
###begin p 32
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C14">14</xref>
###xml 129 131 129 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C14">14</xref></sup>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C17">17</xref>
###xml 478 480 478 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C17">17</xref></sup>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
Serum glucose (G), free fatty acid (FFA), cholesterol, triglyceride (TG), insulin, leptin, and adiponectin levels were determined14 by commercially available tests from fed animals at the end of the 14 days treatment with AngII or saline in WT and P465L heterozygous mice. There were no significant changes in G, TG, FFA, cholesterol, insulin, and leptin levels among groups. Liver was not steatotic in any of the groups at the end of treatment. Dual-energy x-ray absorptiometry17 (Lunar Corp., GE Healthcare, MD, USA) analysis confirmed that total fat percentage and body weight did not change significantly among groups.
###end p 32
###begin title 33
Statistical analysis
###end title 33
###begin p 34
###xml 104 112 102 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post hoc</italic>
###xml 195 196 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F1">1</xref>
###xml 196 196 194 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F2"/>
###xml 196 196 194 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F3"/>
###xml 196 196 194 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F4"/>
###xml 197 198 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F5">5</xref>
###xml 187 198 185 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figures&#160;<xref ref-type="fig" rid="HFP048F1">1</xref><xref ref-type="fig" rid="HFP048F2"/><xref ref-type="fig" rid="HFP048F3"/><xref ref-type="fig" rid="HFP048F4"/>&#8211;<xref ref-type="fig" rid="HFP048F5">5</xref></italic>
###xml 209 210 207 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="HFP048TB2">2</xref>
###xml 203 210 201 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="HFP048TB2">2</xref></italic>
Data are expressed as mean +/- SEM. One-way ANOVA was used to compare data among groups with Bonferroni post hoc test using Graphpad Prism software. Level of significance is indicated in Figures 1-5 and Table 2.
###end p 34
###begin p 35
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 250 251 246 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 271 272 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 568 569 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 143 147 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 462 466 <span type="species:ncbi:10090">mice</span>
(A) The effects of AngII on systolic blood pressure (SBP, mmHg) measured by tail cuff plethysmography in wild-type (WT) and heterozygous P465L mice. AngII increased SBP similarly in WT and P465L PPARgamma mice compared with saline-treated controls. *P < 0.05 vs. day 0. (B) The effects of subcutaneous AngII infusion on heart weight to body weight ratio (Hw/Bw) at the end of 14 days saline (SAL) or angiotensin II (AngII) treatment in WT and P465L heterozygous mice. AngII significantly increased Hw to Bw ratio to a similar degree in WT and P465L PPARgamma groups. *P < 0.05 vs. saline-treated controls.
###end p 35
###begin p 36
###xml 130 134 <span type="species:ncbi:10090">mice</span>
Echocardiographic parameters at day 7 and at day 14 during saline or angiotensin II treatment in wild-type and heterozygous P465L mice
###end p 36
###begin p 37
IVSD, interventricular septal thickness; LVESD, left ventricular end-systolic dimension; LVEDD, left ventricular end-diastolic dimension; FS, fractional shortening; HR, heart rate.
###end p 37
###begin p 38
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
*P < 0.05 vs. WT/Sal or P465L/Sal, respectively.
###end p 38
###begin title 39
Results
###end title 39
###begin title 40
###xml 182 186 <span type="species:ncbi:10090">mice</span>
Angiotensin II administration increases systolic blood pressure and cardiac hypertrophy to a similar extent in wild-type and P465L peroxisomal proliferators activated receptor gamma mice
###end title 40
###begin p 41
###xml 532 533 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F1">1</xref>
###xml 525 533 513 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F1">1</xref></italic>
###xml 842 843 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F1">1</xref>
###xml 835 844 815 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F1">1</xref>B</italic>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 441 445 <span type="species:ncbi:10090">mice</span>
###xml 622 626 <span type="species:ncbi:10090">mice</span>
###xml 657 661 <span type="species:ncbi:10090">mice</span>
We investigated the effect of chronic AngII administration on systolic blood pressure and development of cardiac hypertrophy in WT and PPARgamma defective mice. Baseline systolic blood pressure was not significantly different between the WT and P465L heterozygous mice (100.9 +/- 5.8 vs. 103.2 +/- 7.3 mmHg, respectively). Two weeks administration of AngII increased systolic blood pressure to a similar extent in WT and PPARgamma defective mice. Changes in blood pressure after 7 and 14 days of AngII treatment are shown in Figure 1. No differences were observed in basal heart weight to body weight ratio between WT/SAL mice (4.63 +/- 0.08) and P465L/SAL mice (4.72 +/- 0.06). As expected, AngII treatment significantly increased Hw/Bw ratio, but to a similar extent in both genotypes (5.44 +/- 0.15 vs. 5.62 +/- 0.18, respectively, Figure 1B).
###end p 41
###begin title 42
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Increased cardiac fibrosis in angiotensin II treated P465L mice compared with wild-type mice
###end title 42
###begin p 43
###xml 297 298 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F2">2</xref>
###xml 290 299 286 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F2">2</xref>A</italic>
###xml 748 749 740 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F2">2</xref>
###xml 741 750 733 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F2">2</xref>B</italic>
###xml 841 842 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F2">2</xref>
###xml 834 843 824 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F2">2</xref>B</italic>
###xml 1025 1026 1001 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1049 1050 1025 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F2">2</xref>
###xml 1042 1051 1018 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F2">2</xref>B</italic>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
###xml 538 542 <span type="species:ncbi:10090">mice</span>
###xml 688 692 <span type="species:ncbi:10090">mice</span>
###xml 812 816 <span type="species:ncbi:10090">mice</span>
###xml 897 901 <span type="species:ncbi:10090">mice</span>
Despite having similar increases in blood pressure and heart hypertrophy, the PPARgamma P465L mice developed increased fibrosis in response to AngII compared with WT littermates. Representative images (total of x40 magnification) acquired from paraffin-embedded sections are illustrated in Figure 2A. Picrosirius red staining shows that interstitial collagen staining was minimal in saline-treated WT (i) and P465L (iii) mice, whereas chronic administration of AngII induced a cardiac fibrotic response that was more severe in P465L (iv) mice. Quantification under polarized light (total of x200 magnifications) confirmed a similar degree of basal fibrosis in saline-treated WT and P465L mice (0.48 +/- 0.1 vs. 0.53 +/- 0.04%, respectively, Figure 2B). More importantly, AngII treatment increased fibrosis in WT mice (0.75 +/- 0.17%, Figure 2B) by approximately55% compared with saline-treated WT mice, whereas heterozygous P465L treated with AngII showed a more severe 140% increase in interstitial fibrosis (1.27 +/- 0.3%, P < 0.05 vs. WT, Figure 2B).
###end p 43
###begin p 44
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 359 360 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 468 469 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
(A) Representative images of collagen deposition stained by picrosirius red in saline and AngII-treated WT and P465L mice at total of x40 magnification. (i) WT/SAL, (ii) WT/AngII, (iii) P465L/SAL, and (iv) P465L/AngII. (B) Quantification of fibrosis in saline and angiotensin II treated WT and P465L mice under polarized light at total of x200 magnification (n = 6-10 per group). Six randomly selected areas were quantified and averaged per left ventricular section. *P < 0.05 vs. WT/SAL or WT/AngII groups.
###end p 44
###begin title 45
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Normal functional echocardiographic parameters in angiotensin II treated wild-type and P465L mice
###end title 45
###begin p 46
###xml 84 85 84 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="HFP048TB2">2</xref>
###xml 78 85 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="HFP048TB2">2</xref></italic>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="HFP048TB2">2</xref>
###xml 412 419 412 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="HFP048TB2">2</xref></italic>
###xml 620 621 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="HFP048TB2">2</xref>
###xml 614 621 614 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table&#160;<xref ref-type="table" rid="HFP048TB2">2</xref></italic>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
Under the experimental conditions investigated, no differences in heart rate (Table 2) or functional parameters were found in P465L heterozygous mice and in WT littermates after 14 days AngII treatment. As expected, AngII treatment increased interventricular septal thickness by day 7 in both the WT/AngII and P465L/AngII groups to a similar extent and by day 14 no further increase in hypertrophy was detected (Table 2). Of note, both the left ventricular end-systolic and end-diastolic parameters, as well as fractional shortening were similar in WT and P465L heterozygous mice after 14 days of AngII treatment (Table 2).
###end p 46
###begin title 47
The effect of chronic angiotensin II treatment on hypertrophy and fibrosis marker genes and NADPH oxidase subunit genes
###end title 47
###begin p 48
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F3">3</xref>
###xml 231 240 231 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F3">3</xref>A</italic>
###xml 377 378 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F3">3</xref>
###xml 370 379 366 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F3">3</xref>A</italic>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
We investigated whether ANP and SKMactin, molecular markers of cardiac hypertrophy, were upregulated in our experimental model. No significant differences in basal gene expression between WT/SAL and P465L/SAL groups were observed (Figure 3A), whereas AngII-treated PPARgamma P465L mice showed increased expression of ANP and SKMactin compared with their WT littermates (Figure 3A).
###end p 48
###begin p 49
###xml 455 456 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 476 482 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 482 483 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 506 507 493 494 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">$</sup>
###xml 507 508 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of hypertrophy, fibrosis marker genes, and NADPH oxidase subunit genes in saline and angiotensin II treated WT and P465L mice. Expression of hypertrophy and fibrosis marker genes increased during AngII treatment; this increased expression level was higher in heterozygous P465L mice. PPARgamma1 and adiponectin (AdipoQ, PPARgamma target gene) were not changed significantly among groups. *P < 0.05 vs. WT/SAL; daggerP < 0.05 vs. P465L/SAL; $P < 0.05 vs. WT/AngII.
###end p 49
###begin p 50
###xml 149 156 149 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F3">3</xref>
###xml 308 317 308 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F3">3</xref>B</italic>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F3">3</xref>
###xml 589 598 589 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F3">3</xref>B</italic>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 583 587 <span type="species:ncbi:10090">mice</span>
Similarly, expression of procollagen I and III, osteopontin, and thrombospondin1, genes encoding extracellular matrix proteins typically synthesized de novo during the early phase of fibrosis, was markedly upregulated in AngII-treated heterozygous P465L mice in comparison with AngII-treated WT littermates (Figure 3B). The increased expression of these fibrosis markers agreed with the increased fibrotic response observed histologically. Interestingly, basal expression level of these profibrotic genes did not significantly differ between saline-treated WT and heterozygous P465L mice (Figure 3B).
###end p 50
###begin p 51
###xml 251 252 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C8">8</xref>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C15">15</xref>
###xml 251 255 251 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C8">8</xref>,<xref ref-type="bibr" rid="HFP048C15">15</xref></sup>
###xml 768 769 764 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F3">3</xref>
###xml 761 770 757 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F3">3</xref>C</italic>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
Recent studies indicate that the increased interstitial cardiac fibrosis induced by chronic AngII infusion involves the activation of NADPH oxidases, reactive oxygen species-generating enzymes involved in redox signalling and enhanced gene expression.8,15 We therefore investigated whether alterations in NADPH oxidases may be involved in the enhanced profibrotic effects of AngII in mice with defective PPARgamma function. Measurement of the relative expression of Nox2, Nox4, p22phox, and p67phox subunits of NADPH oxidase in all groups showed that only Nox4 was significantly increased in the AngII-treated P465L mice compared with AngII-treated WT mice, although the other subunits all showed a tendency to increase their mRNA level during AngII treatment (Figure 3C).
###end p 51
###begin title 52
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Angiotensin II reduces adiponectin level in the serum in wild-type but not in P465L heterozygous mice
###end title 52
###begin p 53
###xml 131 133 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C14">14</xref>
###xml 131 133 127 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C14">14</xref></sup>
###xml 235 237 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C14">14</xref>
###xml 235 237 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C14">14</xref></sup>
###xml 533 534 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F4">4</xref>
###xml 526 534 522 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F4">4</xref></italic>
###xml 223 228 <span type="species:ncbi:10090">mouse</span>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
Our group has shown previously that P465L dominant-negative mutation in PPARgamma reduces adiponectin expression in adipose tissue.14 However, this decrease in adiponectin level did not result in insulin resistance in this mouse model.14 We have found that, unlike in P465L heterozygous mice, AngII treatment in WT animals significantly reduced serum adiponectin level compared with saline-treated controls. Interestingly, this level remained significantly higher than that was found in AngII-treated P465L heterozygous mice (Figure 4).
###end p 53
###begin p 54
###xml 157 158 157 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">$</sup>
###xml 158 159 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 181 182 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 202 208 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 208 209 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Serum level of adiponectin in saline and AngII-treated WT and P465L heterozygous mice at the end of 14 days treatment. Level of significance is indicated as $P < 0.001 vs. WT/Sal; *P < 0.01 vs. WT/Sal; daggerP < 0.01 vs. WT/AngII.
###end p 54
###begin title 55
Detection of wild-type and mutant alleles in heart RNA samples
###end title 55
###begin p 56
###xml 156 157 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F5">5</xref>
###xml 149 157 145 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure&#160;<xref ref-type="fig" rid="HFP048F5">5</xref></italic>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 281 285 <span type="species:ncbi:10090">mice</span>
We attempted to detect mutant PPARgamma allele in heterozygous mouse heart samples to confirm the presence of mutated allele. This is illustrated in Figure 5. mRNA expression levels of total PPARgamma was reduced by approximately50% in the P465L heterozygous mice compared with WT mice. In addition to this, the WT and mutant alleles were expressed at similar levels each, one representing approximately50% of the total PPARgamma.
###end p 56
###begin p 57
###xml 193 194 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 201 203 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C16">16</xref>
###xml 201 203 193 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C16">16</xref></sup>
###xml 205 206 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
Expression level of total PPARgamma in wild-type and heterozygous mutant mice and percentage of WT and mutant PPARgamma alleles in the heterozygous mutant mice. Level of probability was set at P < 0.0516 (n = 10 per group).
###end p 57
###begin title 58
Discussion
###end title 58
###begin p 59
###xml 126 133 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 191 196 <span type="species:ncbi:10090">mouse</span>
###xml 220 225 <span type="species:ncbi:9606">human</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
In this study, we show that hypertension induced by chronic AngII administration synergises with defective PPARgamma function in vivo to induce cardiac fibrosis. Using a 'humanized' knock-in mouse model recapitulating a human dominant-negative point mutation in the nuclear receptor PPARgamma, no significant alterations were detected in basal cardiac parameters (e.g. Hw/Bw ratio) or fibrosis level. However, in the presence of AngII-induced hypertension, defective PPARgamma activity resulted in an increased cardiac fibrosis compared with their WT littermates. This differential fibrotic response was not the result of differences in blood pressure or the degree of cardiac hypertrophy, as both WT and heterozygous P465L mice had similar increases in systolic blood pressure up to approximately150 mmHg and their Hw to Bw ratios after AngII treatment were also similar.
###end p 59
###begin p 60
###xml 623 624 623 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C8">8</xref>
###xml 623 624 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C8">8</xref></sup>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C18">18</xref>
###xml 699 701 699 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C18">18</xref></sup>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C19">19</xref>
###xml 781 783 781 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C19">19</xref></sup>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C20">20</xref>
###xml 803 805 803 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C20">20</xref></sup>
Structural remodelling during sustained hypertension is a well-recognized response of the heart which typically results in both cardiomyocyte hypertrophy and interstitial fibrosis. It is driven by numerous mechanisms including mechanical stress and local and systemic neurohumoral pathways such as activation of the renin-angiotensin system. Although hypertrophy and interstitial fibrosis often co-exist, they may to a significant extent be independently regulated. The development of fibrosis involves significant rearrangement of components of the extracellular matrix, increased oxidative stress driven by NADPH oxidase,8 proliferation of fibroblasts, biosynthesis of different collagen isoforms,18 and the upregulation of other membrane-linked glycoproteins such as osteopontin19 and thrombospondin.20 It is known that severe interstitial fibrosis in response to long-term stress may be associated with diastolic dysfunction, arrhythmia, and eventually pump failure.
###end p 60
###begin p 61
###xml 449 451 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C11">11</xref>
###xml 449 451 441 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C11">11</xref></sup>
###xml 569 571 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C21">21</xref>
###xml 569 571 557 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C21">21</xref></sup>
###xml 623 625 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C13">13</xref>
###xml 623 625 611 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C13">13</xref></sup>
###xml 782 783 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C3">3</xref>
###xml 782 783 770 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C3">3</xref></sup>
###xml 436 441 <span type="species:ncbi:10090">mouse</span>
###xml 585 589 <span type="species:ncbi:10116">rats</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
There is data that suggest a beneficial role of PPARgamma in the cardiac remodelling process as indicated by pharmacological evidence that specific PPARgamma ligands may prevent or reduce synthesis and deposition of collagen and other matrix proteins during the fibrotic response. For example, pioglitazone reduced myocardial fibrosis and collagen content during heart failure development, resulting in improved contractile function of mouse hearts.11 Rosiglitazone, another PPARgamma agonist, prevents cardiac fibrosis in mineralocorticoid induced hypertension in rats21 and also, in rats subjected to aortic constriction.13 Finally, ciglitazone inhibited perivascular and interstitial fibrosis in mice that underwent aortic banding, with concomitant improvement of heart function.3
###end p 61
###begin p 62
###xml 465 467 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C22">22</xref>
###xml 465 467 461 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C22">22</xref></sup>
###xml 958 960 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C20">20</xref>
###xml 958 960 947 949 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C20">20</xref></sup>
###xml 1732 1734 1709 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C23">23</xref>
###xml 1732 1734 1709 1711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C23">23</xref></sup>
###xml 1929 1931 1902 1904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C24">24</xref>
###xml 1929 1931 1902 1904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C24">24</xref></sup>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 364 368 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 681 685 <span type="species:ncbi:10090">mice</span>
###xml 938 943 <span type="species:ncbi:9606">human</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
###xml 1067 1071 <span type="species:ncbi:10090">mice</span>
###xml 1509 1513 <span type="species:ncbi:10090">mice</span>
###xml 1979 1984 <span type="species:ncbi:10090">mouse</span>
Using a genetic approach, we have shown in the present study that in the presence of AngII-induced hypertension, expression of the P465L PPARgamma human mutation is associated with increased expression of profibrotic genes such as procollagen I, III, and osteopontin. Previous data have suggested the involvement of osteopontin in myocardial fibrosis and in fact, mice lacking osteopontin are unable to develop fibrosis resulting in accelerated myocardium dilation.22 Our data indicate that osteopontin is barely expressed in the heart of WT and our PPARgamma P465L mice, after AngII-induced hypertension osteopontin is increased up to 17-fold in WT and up to 35-fold in the P465L mice. Other examples of profibrotic genes are thrombospondin 1 and 2, both important regulators of extracellular matrix remodelling by activating TGF-beta. More specifically, there is evidence that thrombospondin 2 seems to contribute to the progression of human heart failure.20 In our study, we found that heterozygous P465L mice had increased thrombospondin 1 level compared with WT mice after AngII treatment and in agreement with increased histological evidence of cardiac fibrosis we also found an increased expression collagen isoforms. Previous studies have suggested that stimulation with extrinsic PPARgamma agonists exerts an anti-fibrotic effect, whereas the current study indicates that endogenous PPARgamma may exert anti-fibrotic effects in the context of hypertension, which are absent in the heterozygous P465L mice. In keeping with this idea, a direct transcriptional repressing effect of PPARgamma has been already shown for osteopontin expression through its binding to a PPAR response element sequence in the osteopontin promoter.23 There is also evidence that PPARgamma dysfunction may directly potentiate collagen synthesis through the interaction of the CIITA/RFX5 transcription factor complex on the collagen gene promoter.24 Taken together, these data suggest that in our mouse model the presence of the dominant-negative PPARgamma mutation may have impaired the repressor function of PPARgamma in preventing cardiac fibrosis during AngII challenge, thereby allowing enhanced transcription of these particular profibrotic genes.
###end p 62
###begin p 63
###xml 462 464 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C10">10</xref>
###xml 462 464 458 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C10">10</xref></sup>
###xml 697 704 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
###xml 553 557 <span type="species:ncbi:10090">mice</span>
###xml 575 579 <span type="species:ncbi:10090">mice</span>
In contrast to the data regarding interstitial fibrosis, angiotensin II did not increase Hw to Bw ratio or Hw to tibia length (data not shown) in heterozygous P465L mice relative to WT mice. This suggests that the pro-fibrotic effects associated with this specific mutant of PPARgamma in the presence of increased AngII levels are distinct from mechanisms driving cardiac hypertrophy at least under these experimental conditions, in contrast to previous studies.10 We also found that there was no overt contractile dysfunction in the heterozygous P465L mice compared with WT mice as assessed by echocardiography, although the presence of more subtle differences remains possible and would require in vivo analyses and/or more prolonged treatment to exclude.
###end p 63
###begin p 64
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C25">25</xref>
###xml 117 119 117 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C25">25</xref></sup>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C26">26</xref>
###xml 338 340 338 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C26">26</xref></sup>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C27">27</xref>
###xml 545 547 545 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C27">27</xref></sup>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C27">27</xref>
###xml 753 755 753 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C27">27</xref></sup>
###xml 110 116 <span type="species:ncbi:9606">humans</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 763 768 <span type="species:ncbi:10090">mouse</span>
Previous data suggest that decreased adiponectin expression may be implicated in heart failure progression in humans.25 Furthermore, in a similar experimental model to ours, adiponectin KO mice during AngII-induced hypertension showed substantially increased interstitial fibrosis as well as cardiac hypertrophy than their WT littermates.26 In a permanent ligation induced chronic heart failure model, the lack of adiponectin significantly increased the level of compensatory hypertrophy, interstitial fibrosis, and left ventricular dysfunction.27 On the contrary, in the same study, adiponectin via adenoviral delivery in WT animals protected the heart against these consequences of chronic ligation of LAD suggesting anti-fibrotic role of adiponectin.27 In our mouse model, P465L dominant-negative mutation in PPARgamma reduced adiponectin expression in the heart and adipose tissue (indicated by lower serum level) which may be contributory to the increased level of cardiac fibrosis under hypertensive conditions. We suggest that reduced adiponectin level in the absence of insulin resistance during this initial phase of hypertension may contribute to increased cardiac fibrosis before left ventricular dysfunction occurs. However, this hypothesis needs confirmation by further studies.
###end p 64
###begin p 65
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C28">28</xref>
###xml 174 176 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C28">28</xref></sup>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C29">29</xref>
###xml 433 435 433 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C29">29</xref></sup>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C30">30</xref>
###xml 448 450 448 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C30">30</xref></sup>
###xml 743 744 743 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C1">1</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C31">31</xref>
###xml 748 750 748 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C32">32</xref>
###xml 743 750 743 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C1">1</xref>,<xref ref-type="bibr" rid="HFP048C31">31</xref>,<xref ref-type="bibr" rid="HFP048C32">32</xref></sup>
###xml 996 997 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F3">3</xref>
###xml 988 997 984 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figures&#160;<xref ref-type="fig" rid="HFP048F3">3</xref></italic>
###xml 1002 1003 998 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="HFP048F4">4</xref>
###xml 1002 1003 998 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="fig" rid="HFP048F4">4</xref></italic>
###xml 1093 1094 1085 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C1">1</xref>
###xml 1093 1094 1085 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C1">1</xref></sup>
###xml 1372 1373 1360 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C1">1</xref>
###xml 1372 1373 1360 1361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C1">1</xref></sup>
###xml 4 9 <span type="species:ncbi:10090">mouse</span>
###xml 56 62 <span type="species:ncbi:9606">humans</span>
###xml 359 365 <span type="species:ncbi:9606">humans</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 736 742 <span type="species:ncbi:9606">humans</span>
###xml 856 860 <span type="species:ncbi:10090">mice</span>
###xml 1041 1047 <span type="species:ncbi:9606">humans</span>
###xml 1114 1118 <span type="species:ncbi:10090">mice</span>
Our mouse model is not insulin resistant in contrast to humans, a difference that likely arises due to discrepancy in the distribution and function of their various fat pads.28 Nevertheless, both direct and indirect roles of adipose tissue in blood pressure regulation (e.g. perivascular fat) and heart function (e.g. epicardial fat) have been established in humans as well as in animal models. For example, adipokines such as leptin29 and visfatin30 in mice have been shown to directly regulate cardiac function under experimental conditions. In addition, insulin resistance depends on the array of adipokines secreted by various visceral and subcutaneous fat pads underlying one particular pathomechanism of the metabolic syndrome in humans.1,31,32 The observed increased fibrotic cardiac (and not metabolic) phenotype in our study in heterozygous P465L mice under hypertension may be the result of altered expression of PPARgamma target genes such as adiponectin in the heart and fat (Figures 3 and 4) but not of leptin. Similar to those humans with dominant-negative mutation in PPARgamma,1 P465L heterozygous mice also have lower expression of adiponectin in adipose tissue as well as in the heart. Another adipose secreted adipokine, leptin which is not regulated by PPARgamma shows no correlation with any of the phenotypes in the presence of the mutation in humans1 and in our study (data not shown).
###end p 65
###begin p 66
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C31">31</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C32">32</xref>
###xml 125 130 125 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C31">31</xref>,<xref ref-type="bibr" rid="HFP048C32">32</xref></sup>
###xml 417 419 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C28">28</xref>
###xml 417 419 409 411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C28">28</xref></sup>
###xml 477 479 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C14">14</xref>
###xml 477 479 469 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C14">14</xref></sup>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 263 268 <span type="species:ncbi:10090">mouse</span>
###xml 347 352 <span type="species:ncbi:10090">mouse</span>
###xml 410 416 <span type="species:ncbi:9606">humans</span>
###xml 608 614 <span type="species:ncbi:10090">murine</span>
From the point of view of relevance to human disease, our data suggest that patients harbouring this mutation or similar ones31,32 may be at increased risk of developing cardiac fibrosis particularly in the context of hypertension. The use of our P465L PPARgamma mouse model to study the role of PPARgamma in the heart has the advantage that this mouse model has a much less severe metabolic phenotype than in humans,28 at least when animals are not in positive energy balance.14 Thus, elucidation of the synergistic effect between defective PPARgamma function and cardiac-specific fibrotic response in this murine model is facilitated in the absence of other complex metabolic phenotypes.
###end p 66
###begin p 67
###xml 54 56 50 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C31">31</xref>
###xml 57 59 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C32">32</xref>
###xml 54 59 50 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C31">31</xref>,<xref ref-type="bibr" rid="HFP048C32">32</xref></sup>
###xml 826 828 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="HFP048C33">33</xref>
###xml 826 828 818 820 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="HFP048C33">33</xref></sup>
###xml 47 53 <span type="species:ncbi:9606">humans</span>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
###xml 629 635 <span type="species:ncbi:9606">humans</span>
###xml 884 892 <span type="species:ncbi:9606">patients</span>
###xml 1046 1052 <span type="species:ncbi:9606">humans</span>
###xml 1141 1147 <span type="species:ncbi:9606">humans</span>
Although these PPARgamma mutations are rare in humans,31,32 these patients exist and in fact it may be possible that their prevalence may increase as increased knowledge allows targeting of specific subsets of patients such as, for example, patients with cardiac phenotypes. Our observations should emphasise that control of blood pressure in these patients may be of paramount importance to prevent cardiac-specific complications. Another less obvious implication is the relevance that these observations may have in the management of more common forms of metabolic syndrome. There is evidence from animal models and studies in humans that in parallel with the development of obesity, insulin resistance, and metabolic alterations, levels of PPARgamma tend to decrease initiating a vicious cycle leading to metabolic failure.33 This suggests that decreased PPARgamma levels in these patients may synergise with highly prevalent hypertension to accelerate cardiac fibrosis. Thus, these considerations should fuel future translational research in humans to elucidate the relevance of the synergy between PPARgamma agonism and hypertension in humans.
###end p 67
###begin p 68
###xml 215 222 211 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
In summary, here we provide evidence using a humanized mouse model recapitulating a well-characterized human mutation that defective PPARgamma function synergises with high blood pressure to induce cardiac fibrosis in vivo. This observation indicates that control of blood pressure should be prioritized in patients affected by these PPARgamma mutations to prevent cardiac complications. We speculate that the knowledge obtained from these experiments also supports the need for strict blood pressure control in other forms of obesity and insulin resistant states where levels of PPARgamma may be decreased in the context of the metabolic syndrome.
###end p 68
###begin title 69
Funding
###end title 69
###begin p 70
###xml 27 51 27 51 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">British Heart Foundation</grant-sponsor>
###xml 53 62 53 62 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RG/03/008</grant-num>
###xml 112 115 112 115 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BHF</grant-sponsor>
A.M.S. is supported by the British Heart Foundation (RG/03/008). A.K., C.M., M.Z., and A.V.P. were supported by BHF. A.V.P. is supported by an MRC career establishment award and MRC CORD. S.G. was supported by Diabetes UK, and M.B. by Wellcome Trust Integrative Physiology Award.
###end p 70
###begin p 71
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest:</bold>
Conflict of interest: none declared.
###end p 71
###begin title 72
Acknowledgements
###end title 72
###begin p 73
Thanks to Sophie Gough for help in editing the manuscript.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma
###end article-title 75
###begin article-title 76
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
###end article-title 76
###begin article-title 77
Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone
###end article-title 77
###begin article-title 78
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
###end article-title 78
###begin article-title 79
Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis
###end article-title 79
###begin article-title 80
ECM remodeling in hypertensive heart disease
###end article-title 80
###begin article-title 81
Hypertension and cardiac arrhythmias
###end article-title 81
###begin article-title 82
Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase
###end article-title 82
###begin article-title 83
Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes
###end article-title 83
###begin article-title 84
###xml 108 116 108 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 121 128 121 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo
###end article-title 84
###begin article-title 85
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction
###end article-title 85
###begin article-title 86
###xml 115 119 <span type="species:ncbi:10116">rats</span>
Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction
###end article-title 86
###begin article-title 87
###xml 120 124 <span type="species:ncbi:10116">rats</span>
Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats
###end article-title 87
###begin article-title 88
###xml 141 145 <span type="species:ncbi:10090">mice</span>
Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator activated receptor gamma function (P465L PPARgamma) in mice
###end article-title 88
###begin article-title 89
Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction
###end article-title 89
###begin article-title 90
Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR
###end article-title 90
###begin article-title 91
Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition
###end article-title 91
###begin article-title 92
Cardiac transcriptional response to acute and chronic angiotensin II treatments
###end article-title 92
###begin article-title 93
###xml 27 30 <span type="species:ncbi:10116">rat</span>
Osteopontin is produced by rat cardiac fibroblasts and mediates AT(II)-induced DNA synthesis and collagen gel contraction
###end article-title 93
###begin article-title 94
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy
###end article-title 94
###begin article-title 95
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension
###end article-title 95
###begin article-title 96
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy
###end article-title 96
###begin article-title 97
PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells
###end article-title 97
###begin article-title 98
Peroxisome proliferator-activated receptor gamma interacts with CIITA x RFX5 complex to repress type I collagen gene expression
###end article-title 98
###begin article-title 99
Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy
###end article-title 99
###begin article-title 100
Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha
###end article-title 100
###begin article-title 101
Adiponectin protects against the development of systolic dysfunction following myocardial infarction
###end article-title 101
###begin article-title 102
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma
###end article-title 102
###begin article-title 103
Leptin, the obesity-associated hormone, exhibits direct cardioprotective effects
###end article-title 103
###begin article-title 104
The novel adipocytokine visfatin exerts direct cardioprotective effects
###end article-title 104
###begin article-title 105
###xml 36 41 <span type="species:ncbi:9606">human</span>
Non-DNA binding, dominant-negative, human PPARgamma mutations cause lipodystrophic insulin resistance
###end article-title 105
###begin article-title 106
###xml 31 36 <span type="species:ncbi:9606">human</span>
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
###end article-title 106
###begin article-title 107
Regulation of PPAR gamma gene expression by nutrition and obesity in rodents
###end article-title 107

